Write your message
Volume 7, Issue 1 (Winter 2022)                   J Obstet Gynecol Cancer Res 2022, 7(1): 38-44 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abd El hafez A. Nuclear Localization of SMAD3 as an Independent Predictor of Recurrence in Ovarian Adult Granulosa Cell Tumor. J Obstet Gynecol Cancer Res. 2022; 7 (1) :38-44
URL: http://jogcr.com/article-1-436-en.html
Professor at Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt , amalabdelhafez@gmail.com
Abstract:   (150 Views)
Background & Objective: Adult granulosa cell tumors (AGCTs) are potentially malignant ovarian neoplasms with a well-known tendency for local spread and recurrence, years after prolonged follow-up. This study investigated the immunohistochemical (IHC) expression of SMAD3 (mothers against decapentaplegic homolog 3) in AGCTs to evaluate its association with a number of confirmed AGCT prognostic variables. Prognostic predictors of recurrence in AGCT were further defined.
Methods: Upon database search, the clinicopathological data, slides, and paraffin blocks of 35 AGCTs were retrospectively retrieved from archives, then examined histopathologically, staged, and stained immunohistochemically using anti-SMAD3. After H scoring of SMAD3, the clinicopathological associations were investigated in positive- and negative-SMAD3 expression groups using appropriate statistical methods. Regression analysis was performed to define independent predictors of recurrence in AGCT.
Results: SMAD3 was actively expressed in the nuclei of 51.4% of AGCTs. It was significantly associated with tumor recurrence, capsular rupture, and size (P=0.011, 0.018, and 0.028, respectively), but not with age, presentation, laterality, stage, tumor morphological pattern, or mitotic index. Capsular rupture and tumor size were defined as highly significant (P≤0.001), as well as SMAD3+ve expression and FIGO stage as significant independent predictors of recurrence (P=0.05 and 0.049, respectively) in AGCT.
Conclusion: SMAD3 is actively expressed in the tumor cell nuclei of around one half of AGCTs and this expression associates with high propensity for tumor recurrence, capsular rupture, and increasing tumor size. Along with the other observed independent predictors of recurrence, SMAD3 may provide an outline for direct discovery of new risk-stratification criteria as well as therapeutic targets for AGCTs.
Full-Text [PDF 635 kb]   (8 Downloads) |   |   Full-Text (HTML)  (10 Views)  
Systematic Review: Original Research | Subject: Pathology
Received: 2021/06/28 | Accepted: 2021/07/10 | Published: 2021/09/9

1. Kottarathil VD, Antony MA, Nair IR, Pavithran K. Recent advances in granulosa cell tumor ovary: a review. Indian J Surg Oncol. 2013;4(1):37-47. [DOI:10.1007/s13193-012-0201-z]
2. Färkkilä A, Haltia UM, Tapper J, McConechy MK, Huntsman DG, Heikinheimo M. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med. 2017;49(5):435-47. [DOI:10.1080/07853890.2017.1294760]
3. Babarović E, Franin I, Klarić M, Ferrari AM, Karnjuš-Begonja R, Eminović S, Ostojić DV, Vrdoljak-Mozetič D. Adult granulosa cell tumors of the ovary: A Retrospective study of 36 FIGO stage I cases with emphasis on prognostic pathohistological features. Anal Cell Pathol (Amst). 2018; 2018:9148124. [DOI:10.1155/2018/9148124]
4. da Cruz Paula A, da Silva EM, Segura SE, Pareja F, Bi R, Selenica P, Kim SH, Ferrando L, Vahdatinia M, Soslow RA, Vidal A, Gatius S, Przybycin CG, Abu-Rustum NR, Matias-Guiu X, Rubin BP, Reis-Filho JS, DeLair DF, Weigelt B. Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Mod Pathol. 2020;33(8):1606-17. [DOI:10.1038/s41379-020-0514-3]
5. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ, Anttonen M. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010;23(11):1477-85. [DOI:10.1038/modpathol.2010.145]
6. Belli M, Secchi C, Stupack D, Shimasaki S. FOXO1 Negates the cooperative action of FOXL2C134W and SMAD-3 in CYP19 Expression in HGrC1 cells by sequestering SMAD-3. J Endocr Soc. 2019;3(11):2064-81. [DOI:10.1210/js.2019-00279]
7. Weis-Banke SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, Sidoli S, Jensen ON, Yanase T, Nakamura T, Iwase A, Stylianou A, Abu-Rustum NR, Aghajanian C, Soslow R, Da Cruz Paula A, Koche RP, Weigelt B, Christensen J, Helin K, Cloos PAC. Mutant FOXL2C134W hijacks SMAD4 and SMAD2/3 to drive adult granulosa cell tumors. Cancer Res. 2020;80(17):3466-79. [DOI:10.1158/0008-5472.CAN-20-0259]
8. Kim SY, Ebbert K, Cordeiro MH, Romero MM, Whelan KA, Suarez AA, Woodruff TK, Kurita T. Constitutive activation of PI3K in oocyte induces ovarian granulosa cell tumors. Cancer Res. 2016;76(13):3851-61. [DOI:10.1158/0008-5472.CAN-15-3358]
9. Ding Q, Jin M, Wang Y, Liu J, Kalds P, Wang Y, Yang Y, Wang X, Chen Y. Transactivation of miR-202-5p by steroidogenic Factor 1 (SF1) induces apoptosis in goat granulosa cells by targeting TGFβR2. cells. 2020;9(2):445. [DOI:10.3390/cells9020445]
10. Fang X, Gao Y, Li Q. SMAD-3 Activation: A converging point of dysregulated TGF-Beta superfamily signaling and genetic aberrations in granulosa cell tumor development? Biol Reprod. 2016;95(5):105. [DOI:10.1095/biolreprod.116.143412]
11. Granados-Aparici S, Hardy K, Franks S, Sharum IB, Waite SL, Fenwick MA. SMAD-3 directly regulates cell cycle genes to maintain arrest in granulosa cells of mouse primordial follicles. Sci Rep. 2019;9(1):6513. [DOI:10.1038/s41598-019-42878-4]
12. Zaloudek CJ, Mooney EE, Staats PN, Young RH. Sex cord-stromal tumors - pure sex cord tumors, In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, (eds). WHO Classification of Tumors of Female Reproductive Organs. 4th edition. Vol. 6 IARC: Lyon, France; 2014 pp 50-3
13. Prat J, FIGO Committee on Gynecologic Oncology. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87-9. [DOI:10.3802/jgo.2015.26.2.87]
14. Anttonen M, Pihlajoki M, Andersson N, Georges A, L'hôte D, Vattulainen S, Färkkilä A, Unkila-Kallio L, Veitia RA, Heikinheimo M. FOXL2, GATA4, and SMAD-3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014;9(1):e85545. [DOI:10.1371/journal.pone.0085545]
15. Yasukawa M, Matsuo K, Matsuzaki S, Dainty LA, Sugarbaker PH. Management of recurrent granulosa cell tumor of the ovary: Contemporary literature review and a proposal of hyperthermic intraperitoneal chemotherapy as novel therapeutic option. J Obstet Gynaecol Res. 2021;47(1):44-51. [DOI:10.1111/jog.14494]
16. Secchi C, Benaglio P, Mulas F, Belli M, Stupack D, Shimasaki S. FOXO1 mitigates the SMAD-3/FOXL2C134W transcriptomic effect in a model of human adult granulosa cell tumor. J Transl Med. 2021;19(1):90. [DOI:10.1186/s12967-021-02754-0]
17. Sakr S, Abdulfatah E, Thomas S, Al-Wahab Z, Beydoun R, Morris R, Ali-Fehmi R, Bandyopadhyay S. Granulosa cell tumors: Novel predictors of recurrence in early-stage patients. Int J Gynecol Pathol. 2017;36(3):240-52. [DOI:10.1097/PGP.0000000000000325]
18. Nosov V, Silva I, Tavassoli F, Adamyan L, Farias-Eisner R, Schwartz PE. Predictors of recurrence of ovarian granulosa cell tumors. Int J Gynecol Cancer. 2009;19(4):628-33. [DOI:10.1111/IGC.0b013e3181a48a6f]
19. Dai F, Lin X, Chang C, Feng XH. Nuclear export of Smad2 and SMAD-3 by RanBP3 facilitates termination of TGF-beta signaling. Dev Cell. 2009;16(3):345-57. [DOI:10.1016/j.devcel.2009.01.022]
20. Amarnath S, Agarwala S. Cell-cycle-dependent TGFβ-BMP antagonism regulates neural tube closure by modulating tight junctions. J Cell Sci. 2017;130(1):119-31. [DOI:10.1242/jcs.179192]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.